Covered recipient · General Payments record
AMANDA BRINK
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2022–2024
$6,990.55
- Reported across 36 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,262.78 | 12 |
| Consulting Fee | $834.00 | 1 |
| Travel and Lodging | $793.07 | 3 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $1,668.22 | 6 |
| Gilead Sciences, Inc. | $323.75 | 3 |
| Spectrum Pharmaceuticals Inc. | $162.42 | 1 |
| Inspire Medical Systems, Inc. | $132.34 | 1 |
| Kyowa Kirin, Inc. | $123.16 | 1 |
| Xeris Pharmaceuticals, Inc. | $122.33 | 1 |
| GENZYME CORPORATION | $121.52 | 1 |
| Apellis Pharmaceuticals, Inc. | $119.53 | 1 |
| UCB, Inc. | $116.58 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $17.05 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115462946 | CMS |
| Amgen Inc. | $27.06 | 11/14/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1115462949 | CMS |
| Amgen Inc. | $381.17 | 11/14/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1115462953 | CMS |
| Amgen Inc. | $834.00 | 11/26/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1117513949 | CMS |
| Amgen Inc. | $24.10 | 11/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117513951 | CMS |
| Amgen Inc. | $384.84 | 11/26/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1117513953 | CMS |
| Apellis Pharmaceuticals, Inc. | $119.53 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154031625 | CMS |
| GENZYME CORPORATION | $121.52 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139893174 | CMS |
| Gilead Sciences, Inc. | $125.00 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133678356 | CMS |
| Gilead Sciences, Inc. | $94.96 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133678358 | CMS |
| Gilead Sciences, Inc. | $103.79 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133678360 | CMS |
| Inspire Medical Systems, Inc. | $132.34 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148137465 | CMS |
| Kyowa Kirin, Inc. | $123.16 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1127046405 | CMS |
| Spectrum Pharmaceuticals Inc. | $162.42 | 09/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150655900 | CMS |
| UCB, Inc. | $116.58 | 08/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143268535 | CMS |
| Xeris Pharmaceuticals, Inc. | $122.33 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144619539 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.